MAPT and Parkinson disease: Studies in the AJ-PD cohort allowed us to stratify them according to subgroups of GBA1 and LRRK2-G2019S mutation carriers and, importantly, to demonstrate that this protective effect of MAPT-H2 is independent of GBA1 and LRRK2 mutation status.